Home » Stocks » ONCT

Oncternal Therapeutics, Inc. (ONCT)

Stock Price: $2.67 USD 0.13 (5.12%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $2.74 +0.07 (2.62%) Nov 27, 4:52 PM

Stock Price Chart

Key Info

Market Cap 59.67M
Revenue (ttm) 2.52M
Net Income (ttm) -18.82M
Shares Out 22.35M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $2.67
Previous Close $2.54
Change ($) 0.13
Change (%) 5.12%
Day's Open 2.59
Day's Range 2.55 - 2.77
Day's Volume 477,488
52-Week Range 1.49 - 6.28

More Stats

Market Cap 59.67M
Enterprise Value 38.79M
Earnings Date (est) Mar 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 22.35M
Float 15.76M
EPS (basic) -0.70
EPS (diluted) -0.58
FCF / Share -0.83
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9,613
Short Ratio 0.21
Short % of Float 0.06%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 23.66
PB Ratio 3.97
Revenue 2.52M
Operating Income -18.86M
Net Income -18.82M
Free Cash Flow -16.63M
Net Cash 20.88M
Net Cash / Share 0.93
Gross Margin -306.54%
Operating Margin -747.90%
Profit Margin -746.40%
FCF Margin -659.36%
ROA -48.51%
ROE -111.22%
ROIC 341.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.00*
Low
8.00
Current: $2.67
High
8.00
Target: 8.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2.432.52------8.0756.79
Revenue Growth-3.81%--------85.8%-
Gross Profit2.432.52------8.0756.79
Operating Income-33.11-7.59-30.66-25.93-21.84-30.35-43.60-49.73-35.9015.10
Net Income-34.19-6.58-30.44-17.72-18.70-39.41-42.11-27.08-33.2915.29
Shares Outstanding10.333.592.492.082.011.170.900.900.820.56
Earnings Per Share-3.31-1.83-12.25-8.54-10.29-33.74-46.90-30.10-40.6027.30
Operating Cash Flow-16.75-7.42-23.46-20.78-20.04-28.76-43.97-37.11-33.09-30.53
Capital Expenditures----0.09--0.011.39-0.14-0.05-0.10
Free Cash Flow-16.75-7.42-23.46-20.87-20.04-28.76-42.58-37.25-33.14-30.62
Cash & Equivalents20.0520.6543.9021.8729.2649.3014.7356.0974.4458.63
Total Debt0.19---------
Net Cash / Debt19.8620.6543.9021.8729.2649.3014.7356.0974.4458.63
Assets21.7421.9646.2424.5032.0350.6515.6157.7778.6664.25
Liabilities7.4351.597.984.6130.1732.824.9210.076.7812.52
Book Value14.31-29.6338.2619.891.8617.8310.6847.7071.8751.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oncternal Therapeutics, Inc.
Country United States
Employees 11
CEO James B. Breitmeyer

Stock Information

Ticker Symbol ONCT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ONCT

Description

Oncternal Therapeutics, a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. It also develops TK-216, a small-molecule that is designed to inhibit E26 transformation specific family of oncoproteins, which is in Phase I clinical trial to treat patients with Ewing sarcoma and in combination with vincristine chemotherapy. In addition, the company develops a chimeric antigen receptor-T product candidate that targets ROR1, which is in preclinical development for treating hematologic cancers and solid tumors. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.